Company Analysis
Sign in

Corvus Pharmaceuticals, Inc. (CRVS)

Nasdaq: CRVS · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2014
Full chart Alerts Compare
Grade5.1
◀ Past 5.1● Present 6.3▶ Future 4.1
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

15 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Corvus Pharmaceuticals, Inc.’s names, not what it holds today.

Patents granted
15
15 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 5 in 2024 and none in 2023
Applications published
25
1 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'18'19'20'21'22'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals6
Organic fine chemistry3
Analysis of biological materials1
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Corvus Pharmaceuticals, Inc. its own name
named as the applicant on its applications, in US
0 granted
24 published
Corvus Pharmaceuticals, Inc. its own name
US, as the owner printed on each patent
15 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jul 8, 202512,351,644Anti-CD73 antibodiesPharmaceuticalsCorvus Pharmaceuticals, Inc.
Dec 24, 202412,174,192Methods for detecting and treating cancers having adenosine pathway activationPharmaceuticalsCorvus Pharmaceuticals, Inc.
Oct 15, 202412,116,635Methods for detecting and treating cancers having adenosine pathway activationBiotechnologyCorvus Pharmaceuticals, Inc.
Jul 2, 202412,023,337Methods of treating cancerPharmaceuticalsCorvus Pharmaceuticals, Inc.
Feb 13, 202411,897,874Compounds and methods for modulating Interleukin-2-inducible T-cell kinaseOrganic fine chemistryCorvus Pharmaceuticals, Inc.
Jan 2, 202411,859,007Humanized anti-CD73 antibodiesAnalysis of biological materialsCorvus Pharmaceuticals, Inc.
Mar 8, 202211,266,649Pharmaceutical formulationsPharmaceuticalsCorvus Pharmaceuticals, Inc.
Feb 22, 202211,254,686Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptorOrganic fine chemistryCorvus Pharmaceuticals, Inc.
Jun 22, 202111,040,040Methods of treating cancerPharmaceuticalsCorvus Pharmaceuticals, Inc.
May 18, 202111,008,314Compounds and methods for modulating interleukin-2-inducible t-cell kinaseOrganic fine chemistryCorvus Pharmaceuticals, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jul 3, 20252025/0213587ITK INHIBITORS FOR INCREASING TH1 CELL ACTIVITYPharmaceuticalsCorvus Pharmaceuticals, Inc.
Nov 21, 20242024/0383884COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASEOrganic fine chemistryCorvus Pharmaceuticals, Inc.
Sep 12, 20242024/0301082ANTI-CD73 COMPOUNDS TO TREAT ONCOVIRUS-POSITIVE CANCERSPharmaceuticalsCorvus Pharmaceuticals, Inc.
Jul 4, 20242024/0218073IMMUNOMODULATORY ANTI-CD73 ANTIBODIES AND USES THEREOFPharmaceuticalsCorvus Pharmaceuticals, Inc.
Nov 17, 20222022/0363676COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASEOrganic fine chemistryCorvus Pharmaceuticals, Inc. · patent 11,897,874 granted from it
Aug 4, 20222022/0242963B-CELL ACTIVATING CD73 ANTIBODIESPharmaceuticalsCorvus Pharmaceuticals, Inc.
Aug 19, 20212021/0255190METHODS FOR DETECTING AND TREATING CANCERS HAVING ADENOSINE PATHWAY ACTIVATIONPharmaceuticalsCorvus Pharmaceuticals, Inc. · patent 12,174,192 granted from it
Aug 19, 20212021/0254178METHODS FOR DETECTING AND TREATING CANCERS HAVING ADENOSINE PATHWAY ACTIVATIONBiotechnologyCorvus Pharmaceuticals, Inc. · patent 12,116,635 granted from it
Aug 19, 20212021/0253727HUMANIZED ANTI-CD73 ANTIBODIESAnalysis of biological materialsCorvus Pharmaceuticals, Inc. · patent 11,859,007 granted from it
Jul 22, 20212021/0221905ANTI-CD73 ANTIBODIESPharmaceuticalsCorvus Pharmaceuticals, Inc. · patent 12,351,644 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 3 · Organic fine chemistry 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton CRVS · research, not advice